Taysha Gene Therapies (TSHA) Acquires Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program

Taysha Gene Therapies (TSHA) PT Raised to $67.50 at Chardan Capital Markets

Chardan Capital Markets analyst Gbola Amusa raised the price target on Taysha Gene Therapies (NASDAQ: TSHA) to $67.50 (from $60.00) while maintaining a Buy rating.

The analyst commented, "This morning, Taysha Gene Therapies (Buy) announced the acquisition of exclusive worldwide rights to AAV9-based gene... More